MMP9 has also been considered as an indicator of invasiveness in malignant melanoma and a marker of treatment by BRAF (B-Raf proto-oncogene, serine/threonine kinase) inhibitors, a common genetic mutation in melanoma (38). This evidence concerns the gene MARK2 and melanoma.